Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cymbalta improves sleep in diabetic nerve damage patients
Patients with pain caused by diabetic nerve damage, or diabetic peripheral neuropathy, who are treated with Cymbalta showed improvements in both average daily pain and night pain severity,
Patients with pain caused by diabetic nerve damage, or diabetic peripheral neuropathy, who are treated with Cymbalta showed improvements in both average daily pain and night pain severity,
Femara tablets had US sales of approximately $326 million for the same strength for 2006, according to IMS Health. However, Novartis plans to defend its intellectual property rights
ARRY-520 is a potent kinesin spindle protein inhibitor that caused marked tumor regression in preclinical models of human cancer at tolerated doses, often leading to complete, durable responses.
Preliminary results of the clinical study showed that six months of treatment with doses of Iplex up to 1mg/kg/day in six patients met the primary study endpoints of
The schedule II designator is applied to drugs considered to have a high likelihood of being abused and additional prescribing safeguards are put in place. Shire said that
Tysabri was temporarily withdrawn from the US market in 2005 after three cases of progressive multifocal leukoencephalopathy, or PML, in patients taking it in clinical trials. Two of
The antibody was generated using Medarex’s UltiMAb technology and is the second UltiMAb-derived antibody to be advanced into phase II clinical development by Amgen. Medarex may receive future
Symptomatic venous thromboembolism (VTE) is the formation of a blood clot that can travel from a leg vein to the lung, with potentially fatal results. Fragmin is the
The proposed labeling changes also state that studies did not show this increased risk in adults older than 24, and that adults ages 65 and older taking antidepressants
The phase II clinical trial will be based at the Texas Heart Institute, and will follow a similar protocol to the one used by the same investigators in